Cobalis Corporation

Cobalis Corp. (OTCBB: CLSC), headquartered in Irvine, California, is dedicated to developing and bringing to the consumer marketplace unique over-the-counter (OTC) products for the reduction, management and prevention of allergic diseases.

The Company’s premier product, PreHistin™, represents Cobalis’ commitment to creating innovative new approaches to allergy management and to empowering consumers to take greater control of their health profiles.

 
 CLSC.PK
Date 8/9/2010
Time 3:29pm ET
Trade 0.12
Change 0.00
% Chg 0.00%
Open 0.00
High 0.00
Low 0.00
Volume 0
Intraday 
Powered by JoomlaGadgets

Premier Products
Cobalis Product Pipeline

PreHistin™ is intended to become the first-ever medication aimed specifically at rectifying imbalances in the immune system that trigger the over-production of allergy symptom-causing substances, including histamines. By preventing or reducing the over-production of histamines before they are released, the need to block the symptom-causing effects of histamine is eliminated, as is the need to rely on antihistamines.

Cobalis’ approach makes good sense when compared to the current paradigm of blocking the action of already-produced symptom-causing substances with antihistamines or other drugs, which often result in debilitating and uncomfortable side-effects. PreHistin™, as a preventative approach to allergic disease, becomes The World’s First Pre-Histamine™.

Our patents have broad claims covering all of the above-mentioned allergic diseases. The patents describe the use of cobalamin for reducing “…the symptoms and IgE antibodies associated with allergic diseases.”
 

IMPORTANT NOTICE:
The FDA has not completed evaluation of PreHistin™, and the information and statements contained in this web site are intended for informational purposes only. They are not meant to imply a cure or approved treatment for any disease or condition. You are encouraged to consult your physician for any healthcare questions or concerns you may have about your allergies.